Guidance

12 Sources of evidence considered by the Committee

12 Sources of evidence considered by the Committee

The diagnostics assessment report was prepared by the School of Health and Related Research (ScHARR).

  • Ward S, Scope A, Rachid R et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management, October 2011.

Registered stakeholders

The following organisations accepted the invitation to participate in this assessment as stakeholders. They were invited to attend the scoping workshop and to comment on the diagnostics assessment report and the diagnostics consultation document.

Manufacturers/sponsors:

The technologies under consideration

  • Agendia Bvd (MammaPrint)

  • Clarient (Mammostrat)

  • Genomic Health (Oncotype DX)

  • Royal Marsden Hospital and Queen Mary University London – academic sponsor (IHC4)

Comparator technologies

  • None

Other

  • ARUP Laboratories

  • Ipsogen

  • Nottingham University

  • Randox Laboratories

  • Roche Diagnostics

Professional/specialist and patient/carer groups:

  • BHR University NHS Trust

  • Breakthrough Breast Cancer

  • Bupa

  • Cambridge University Hospital

  • Cherry Lodge Cancer Care

  • Mersey and Cheshire Cancer Network

  • Royal College of Physicians

  • Southport and Ormskirk Hospital NHS Trust

  • The Royal College of Pathologists

  • University College London Hospitals NHS Foundation Trust

  • University Hospital of South Manchester

  • National Institute for Health and Care Excellence (NICE)